ABIONYX Pharma SA (609) Stock Statistics & Valuation Metrics
Total Valuation
ABIONYX Pharma SA has a market cap or net worth of EUR 70.84M. The enterprise value is EUR 62.06M.
- Market Cap
- EUR 70.84M
- Enterprise Value
- EUR 62.06M
Share Statistics
ABIONYX Pharma SA has 44,067,715 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 44,067,715
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
ABIONYX Pharma SA’s return on equity (ROE) is -1.30 and return on invested capital (ROIC) is -65.53%.
- Return on Equity (ROE)
- -1.30
- Return on Assets (ROA)
- -0.43
- Return on Invested Capital (ROIC)
- -65.53%
- Return on Capital Employed (ROCE)
- -0.81
- Revenue Per Employee
- 82.92K
- Profits Per Employee
- -113.27K
- Employee Count
- 49
- Asset Turnover
- 0.32
- Inventory Turnover
- 14.46
Valuation Ratios
The current PE Ratio of ABIONYX Pharma SA is -7.32. ABIONYX Pharma SA’s PEG ratio is 0.14.
- PE Ratio
- -7.32
- PS Ratio
- 18.26
- PB Ratio
- 3.71
- Price to FCF
- -20.78
- Price to Operating Cash Flow
- -17.75
- PEG Ratio
- 0.14
Income Statement
In the last 12 months, ABIONYX Pharma SA had revenue of 4.06M and earned -5.55M in profits. Earnings per share was -0.16.
- Revenue
- 4.06M
- Gross Profit
- 376.00K
- Operating Income
- -6.25M
- Pretax Income
- -6.24M
- Net Income
- -5.55M
- EBITDA
- -5.70M
- Earnings Per Share (EPS)
- -0.16
Cash Flow
In the last 12 months, operating cash flow was -3.28M and capital expenditures -130,000, giving a free cash flow of -3.41M billion.
- Operating Cash Flow
- -3.28M
- Free Cash Flow
- -3.41M
- Free Cash Flow per Share
- -0.09
Dividends & Yields
ABIONYX Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.81%
- Earnings Yield
- -13.86%
Stock Price Statistics
- Beta
- -0.32
- 52-Week Price Change
- -63.57%
- 50-Day Moving Average
- 1.69
- 200-Day Moving Average
- 2.59
- Relative Strength Index (RSI)
- 54.23
- Average Volume (3m)
- 6,633
Important Dates
ABIONYX Pharma SA upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 23, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
ABIONYX Pharma SA as a current ratio of 1.06, with Debt / Equity ratio of 89.30%
- Current Ratio
- 1.06
- Quick Ratio
- 1.01
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- -0.05
- Interest Coverage Ratio
- -31.27
Taxes
In the past 12 months, ABIONYX Pharma SA has paid -688.00K in taxes.
- Income Tax
- -688.00K
- Effective Tax Rate
- 0.11
Enterprise Valuation
ABIONYX Pharma SA EV to EBITDA ratio is -10.11, with an EV/FCF ratio of -17.35.
- EV to Sales
- 15.24
- EV to EBITDA
- -10.11
- EV to Free Cash Flow
- -17.35
- EV to Operating Cash Flow
- -18.04
Balance Sheet
ABIONYX Pharma SA has EUR 26.87M in cash and marketable securities with EUR 15.18M in debt, giving a net cash position of EUR 11.69M billion.
- Cash & Marketable Securities
- EUR 26.87M
- Total Debt
- EUR 15.18M
- Net Cash
- EUR 11.69M
- Net Cash Per Share
- EUR 0.27
- Tangible Book Value Per Share
- EUR 0.28
Margins
Gross margin is 5.39%, with operating margin of -168.02%, and net profit margin of -207.84%.
- Gross Margin
- 5.39%
- Operating Margin
- -168.02%
- Pretax Margin
- -233.84%
- Net Profit Margin
- -207.84%
- EBITDA Margin
- -150.84%
- EBIT Margin
- -167.76%
Analyst Forecast
The average price target for ABIONYX Pharma SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -10.38%
- EPS Growth Forecast
- -72.05%
